What is the average price of pioglitazone exports from India?

The average unit price for pioglitazone exports from India is $0.91 USD per unit, with prices ranging from $0.00 to $78.88 depending on formulation, packaging, and order volume. The total market is valued at $37.3M across 2,674 shipments.

Which ports handle pioglitazone exports from India?

The primary ports for pioglitazone exports from India are DELHI AIR (9.3% of shipments), HYDERABAD ICD (8.6% of shipments), DELHI AIR CARGO ACC (INDEL4) (7.7% of shipments), SAHAR AIR (7.7% of shipments), HYDERABAD ICD (INSNF6) (7.6% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Why is India a leading exporter of pioglitazone?

India is one of the world's leading exporters of pioglitazone due to its large base of 115 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports pioglitazone to 70 countries, demonstrating 36% global market coverage.

What certifications do Indian pioglitazone exporters need?

Indian pioglitazone exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

How many buyers import pioglitazone from India?

There are 293 registered buyers importing pioglitazone from India, spread across 70 countries. The repeat buyer rate is 73.4%, indicating strong long-term trade relationships and consistent product quality.

What is the market share of the top pioglitazone supplier from India?

AUROBINDO PHARMA LTD is the leading pioglitazone exporter from India with a market share of 40.7% and total export value of $15.2M across 547 shipments. The top 5 suppliers together control 74.2% of total export value.

Pioglitazone

India Pharmaceutical Trade Intelligence

$37.3M115 Suppliers70 CountriesHS 30049099

ExportsIndia → UNITED STATES60.5%India → PHILIPPINES7.8%

ImportsUNITED STATES → India$30.6K BRAZIL → India$4.5K

#1 Buyer: RISING PHARMA

Pioglitazone Export Data from India (2026) — Suppliers, Buyers & Trade Stats | TransData Nexus | TransData Nexus

How India Exports Pioglitazone to the World

Q: Who are the top pioglitazone exporters from India?

The top pioglitazone exporters from India are: 1. AUROBINDO PHARMA LTD — $15.2M (40.7% market share); 2. AUROBINDO PHARMA LIMITED — $4.0M (10.8% market share); 3. INTAS PHARMACEUTICALS LIMITED — $3.4M (9.1% market share); 4. MACLEODS PHARMACEUTICALS LTD — $3.3M (8.9% market share); 5. AJANTA PHARMA LIMITED — $1.8M (4.7% market share). Together they account for 74.2% of India's total pioglitazone export value.

Q: What is the total export value of pioglitazone from India?

The total export value of pioglitazone from India is $37.3M USD, recorded across 2,674 shipment transactions from 115 active exporters to 70 destination countries. The average shipment value is $13.9K.

Q: Which countries import pioglitazone from India?

India exports pioglitazone to 70 countries worldwide. The top importing countries are: UNITED STATES (60.5% share, $22.6M), PHILIPPINES (7.8% share, $2.9M), ITALY (3.2% share, $1.2M), JAMAICA (3.0% share, $1.1M), CROATIA (2.8% share, $1.1M). These five markets account for 77.3% of total export value.

Q: What is the HS code for pioglitazone exports from India?

The primary HS code for pioglitazone exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Between 2022 and 2026, India exported $37.3M worth of pioglitazone across 2,674 verified shipments to 70 countries — covering 36% of world markets in the Diabetes & Endocrine segment. The largest destination is UNITED STATES (60.5%). AUROBINDO PHARMA LTD leads with a 40.7% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Pioglitazone export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Pioglitazone export data snapshot — $37.3M · 115 exporters · 70 countriesTransData Nexus · Indian Customs Data

Top Pioglitazone Exporters from India

115 active exporters · Ranked by export value

View all 115 →

Top Pioglitazone Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	AUROBINDO PHARMA LTD	$15.2M	547	4	40.7%
2	AUROBINDO PHARMA LIMITED

Top Countries Importing Pioglitazone from India

70 destination markets · Ranked by import value

All 70 countries →

Top Countries Importing Pioglitazone from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$22.6M	60.5%
2	PHILIPPINES	$2.9M	7.8%
3	ITALY	$1.2M	3.2%
4	JAMAICA	$1.1M	3.0%
5	CROATIA	$1.1M	2.8%
6	UNITED KINGDOM	$977.5K	2.6%
7	IRAQ	$820.5K	2.2%
8	BRAZIL	$694.6K	1.9%
9	POLAND	$649.6K	1.7%
10	QATAR	$550.9K	1.5%

UNITED STATES is India's largest pioglitazone export destination, absorbing 60.5% of total exports worth $22.6M. The top 5 importing countries — UNITED STATES, PHILIPPINES, ITALY, JAMAICA, CROATIA — together account for 77.3% of India's total pioglitazone export value. The remaining 65 destination countries collectively receive the other 22.7%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Pioglitazone to India?

10 origin countries · Total import value: $48.5K

India imports pioglitazone from 10 countries with a combined import value of $48.5K. The largest supplier is UNITED STATES ($30.6K, 8 shipments), followed by BRAZIL and MALTA. All values are from Indian Customs (DGFT) import records.

Countries Supplying Pioglitazone to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$30.6K	8	63.2%
2	BRAZIL	$4.5K	7	9.2%
3	MALTA	$4.1K	23	8.4%
4	GERMANY	$3.2K	5	6.6%
5	UNITED KINGDOM	$2.3K	2	4.7%
6	IRELAND	$2.2K	2	4.6%
7	BULGARIA	$1.1K	1	2.3%
8	HUNGARY	$256	2	0.5%
9	NETHERLANDS	$202	1	0.4%
10	TAIWAN	$10	2	0.0%

UNITED STATES is the largest supplier of pioglitazone to India, accounting for 63.2% of total import value. The top 5 origin countries — UNITED STATES, BRAZIL, MALTA, GERMANY, UNITED KINGDOM — together supply 92.2% of India's pioglitazone imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Pioglitazone

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, pioglitazone has been approved through the Abbreviated New Drug Application (ANDA) pathway, allowing generic versions to enter the market. The FDA's Orange Book lists multiple approved ANDAs for pioglitazone, indicating a competitive generic landscape. Notably, there have been no recent import alerts or significant regulatory actions affecting pioglitazone imports from India. This stable regulatory environment has facilitated consistent exports from India, with 115 active exporters contributing to the U.S. market.

2EU & UK Regulatory Framework

In the European Union, pioglitazone has been subject to various regulatory actions. For instance, the marketing authorization for Glidipion (pioglitazone) was withdrawn on 19 July 2021 at the request of the marketing authorization holder, Actavis Group PTC ehf, due to commercial reasons. Similarly, the marketing authorization for Glubrava (pioglitazone/metformin hydrochloride) was withdrawn on 24 May 2022 at the request of Takeda Pharma A/S. These withdrawals reflect commercial decisions rather than safety or efficacy concerns. Manufacturers exporting to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined by the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

3WHO Essential Medicines & Global Standards

Pioglitazone is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in global health. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

4India Regulatory Classification

In India, pioglitazone is classified under Schedule H, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set ceiling prices for pioglitazone formulations to ensure affordability; for example, the price for pioglitazone 15 mg tablets was capped in July 2025. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pioglitazone, ensuring compliance with national regulations.

5Patent & Exclusivity Status

The primary patents for pioglitazone have expired, leading to increased generic competition globally. This has resulted in a diversified market with multiple manufacturers producing generic versions, contributing to the substantial export figures from India.

6Recent Industry Developments

In August 2025, the NPPA revised the ceiling price for pioglitazone 30 mg tablets, reducing it by 5% to enhance affordability. In October 2025, the FDA approved a new generic version of pioglitazone, further intensifying market competition. In December 2025, the EMA issued updated guidelines on the use of pioglitazone, emphasizing monitoring for potential adverse effects. In January 2026, the Indian government introduced new export incentives for pharmaceutical products, including pioglitazone, to boost international trade. In March 2026, the WHO updated its Essential Medicines List, reaffirming the inclusion of pioglitazone for the treatment of type 2 diabetes.

These developments reflect the dynamic regulatory and market landscape for pioglitazone, influencing both domestic policies and international trade.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Pioglitazone

Retail & reference prices across 9 markets vs. India FOB export price of $0.91/unit

Global Price Benchmark for Pioglitazone across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$0.50	USD	According to the FDA's Orange Book, Pioglitazone is available as a generic medication, contributing to its affordability.
United Kingdom	$0.55	GBP	The NHS Drug Tariff lists Pioglitazone as a reimbursable item, ensuring regulated pricing within the healthcare system.
Germany	$0.50	EUR	The Federal Institute for Drugs and Medical Devices (BfArM) includes Pioglitazone in its list of approved medications, with pricing subject to statutory health insurance regulations.
Australia

Supply Chain Risk Assessment — Pioglitazone

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, while robust in manufacturing finished formulations, heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 60–70% of these essential components are sourced from China. This dependency poses a significant risk, as any disruption in the supply chain from China—be it due to geopolitical tensions, trade restrictions, or production issues—can adversely affect the availability and cost of APIs necessary for producing medications like pioglitazone.

In recent years, efforts have been made to reduce this dependency. The Indian government's Production Linked Incentive (PLI) scheme, initiated in 2021, aims to bolster domestic production of critical APIs and KSMs. However, as of March 2026, the impact of this initiative on reducing import reliance remains limited, and the industry continues to be vulnerable to external supply chain disruptions.

2Supplier Concentration & Single-Source Risk

The export market for pioglitazone is notably concentrated. The top five exporters—led by AUROBINDO PHARMA LTD with a 40.7% share—collectively account for 74.2% of the total export value. Such concentration increases the risk of supply disruptions. If any of these key suppliers face operational challenges, regulatory issues, or other unforeseen events, the global supply of pioglitazone could be significantly impacted.

Access Complete Pioglitazone Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 2,674 transactions across 70 markets.

Request Demo View Pricing

Frequently Asked Questions — Pioglitazone Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top pioglitazone exporters from India?

The leading pioglitazone exporters from India are AUROBINDO PHARMA LTD, AUROBINDO PHARMA LIMITED, INTAS PHARMACEUTICALS LIMITED, and 12 others. AUROBINDO PHARMA LTD leads with 40.7% market share ($15.2M). The top 5 suppliers together control 74.2% of total export value.

What is the total export value of pioglitazone from India?

The total export value of pioglitazone from India is $37.3M, recorded across 2,674 shipments from 115 active exporters to 70 countries. The average shipment value is $13.9K.

Which countries import pioglitazone from India?

India exports pioglitazone to 70 countries. The top importing countries are UNITED STATES (60.5%), PHILIPPINES (7.8%), ITALY (3.2%), JAMAICA (3.0%), CROATIA (2.8%), which together account for 77.3% of total export value.

What is the HS code for pioglitazone exports from India?

The primary HS code for pioglitazone exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Pioglitazone

Pioglitazone

Top Pioglitazone Exporters from India

Top Countries Importing Pioglitazone from India

Who Supplies Pioglitazone to India?

Quick Facts

Related Diabetes & Endocrine

Related Analysis

Need Details?

Regulatory Landscape — Pioglitazone

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Pioglitazone

Supply Chain Risk Assessment — Pioglitazone

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Pioglitazone Trade Intelligence

Frequently Asked Questions — Pioglitazone Exports from India

Who are the top pioglitazone exporters from India?

What is the total export value of pioglitazone from India?

Which countries import pioglitazone from India?

What is the HS code for pioglitazone exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of pioglitazone exports from India?

Which ports handle pioglitazone exports from India?

Why is India a leading exporter of pioglitazone?

What certifications do Indian pioglitazone exporters need?

How many buyers import pioglitazone from India?

What is the market share of the top pioglitazone exporter from India?

Analysis Methodology